acetazolamide has been researched along with Muscle Weakness in 8 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Muscle Weakness: A vague complaint of debility, fatigue, or exhaustion attributable to weakness of various muscles. The weakness can be characterized as subacute or chronic, often progressive, and is a manifestation of many muscle and neuromuscular diseases. (From Wyngaarden et al., Cecil Textbook of Medicine, 19th ed, p2251)
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 46-year-old man with hypokalemic periodic paralysis (HypoPP) and diabetes mellitus (DM) had worsened muscle weakness after acetazolamide (ACZ) treatment." | 7.71 | Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. ( Ichikawa, Y; Igarashi, O; Ikeda, K; Iwasaki, Y; Kinoshita, M; Satoyoshi, E; Yabuki, D, 2002) |
| "A 46-year-old man with hypokalemic periodic paralysis (HypoPP) and diabetes mellitus (DM) had worsened muscle weakness after acetazolamide (ACZ) treatment." | 3.71 | Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis. ( Ichikawa, Y; Igarashi, O; Ikeda, K; Iwasaki, Y; Kinoshita, M; Satoyoshi, E; Yabuki, D, 2002) |
| "Hypokalaemic periodic paralysis (hypoPP) is the archetypal skeletal muscle channelopathy caused by dysfunction of one of two sarcolemmal ion channels, either the sodium channel Nav1." | 2.46 | Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis? ( Hanna, MG; Matthews, E, 2010) |
| "We report a 65 year-old man with hyperkalemic periodic paralysis and late-onset permanent weakness in association with the common T704M mutation in α-subunit, skeletal muscle voltage-gated sodium channel gene." | 1.39 | Long-term effectiveness of acetazolamide on permanent weakness in hyperkalemic periodic paralysis. ( Dejthevaporn, C; Jaovisidha, S; Papsing, C; Phakdeekitcharoen, B; Phudhichareonrat, S; Pulkes, T; Witoonpanich, R, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stunnenberg, BC | 2 |
| LoRusso, S | 2 |
| Arnold, WD | 1 |
| Barohn, RJ | 1 |
| Cannon, SC | 1 |
| Fontaine, B | 1 |
| Griggs, RC | 1 |
| Hanna, MG | 2 |
| Matthews, E | 2 |
| Meola, G | 1 |
| Sansone, VA | 1 |
| Trivedi, JR | 1 |
| van Engelen, BGM | 1 |
| Vicart, S | 1 |
| Statland, JM | 1 |
| Gupta, A | 1 |
| Iyadurai, S | 1 |
| Roggenbuck, J | 1 |
| van Osch, T | 1 |
| Sternberg, D | 1 |
| Kerklaan, BJ | 1 |
| Dejthevaporn, C | 1 |
| Papsing, C | 1 |
| Phakdeekitcharoen, B | 1 |
| Jaovisidha, S | 1 |
| Phudhichareonrat, S | 1 |
| Witoonpanich, R | 1 |
| Pulkes, T | 1 |
| Ma, Y | 1 |
| Li, M | 1 |
| Jiao, LQ | 1 |
| Zhang, HQ | 1 |
| Ling, F | 1 |
| Lehmann-Horn, F | 1 |
| Orth, M | 1 |
| Kuhn, M | 1 |
| Jurkat-Rott, K | 1 |
| Ikeda, K | 1 |
| Iwasaki, Y | 1 |
| Kinoshita, M | 1 |
| Yabuki, D | 1 |
| Igarashi, O | 1 |
| Ichikawa, Y | 1 |
| Satoyoshi, E | 1 |
3 reviews available for acetazolamide and Muscle Weakness
| Article | Year |
|---|---|
Guidelines on clinical presentation and management of nondystrophic myotonias.
Topics: Acetazolamide; Age of Onset; Carbonic Anhydrase Inhibitors; Chloride Channels; Electrodiagnosis; Ele | 2020 |
Marked reduction in paralytic attacks in a patient with Andersen-Tawil syndrome switched from acetazolamide to dichlorphenamide.
Topics: Acetazolamide; Andersen Syndrome; Carbonic Anhydrase Inhibitors; Dichlorphenamide; Female; Humans; M | 2021 |
Muscle channelopathies: does the predicted channel gating pore offer new treatment insights for hypokalaemic periodic paralysis?
Topics: Acetazolamide; Animals; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Channelopathies; Humans; | 2010 |
5 other studies available for acetazolamide and Muscle Weakness
| Article | Year |
|---|---|
Prolonged attacks of weakness with hypokalemia in SCN4A-related paramyotonia congenita.
Topics: Acetazolamide; Carbonic Anhydrase Inhibitors; Electromyography; Humans; Hypokalemia; Male; Middle Ag | 2018 |
Long-term effectiveness of acetazolamide on permanent weakness in hyperkalemic periodic paralysis.
Topics: Acetazolamide; Aged; Humans; Male; Muscle Weakness; Mutation; Paralysis, Hyperkalemic Periodic; Time | 2013 |
Contralateral cerebral hemodynamic changes after unilateral direct revascularization in patients with moyamoya disease.
Topics: Acetazolamide; Adolescent; Adult; Carotid Arteries; Cerebral Angiography; Cerebral Revascularization | 2011 |
A novel N440K sodium channel mutation causes myotonia with exercise-induced weakness--exclusion of CLCN1 exon deletion/duplication by MLPA.
Topics: Acetazolamide; Anti-Arrhythmia Agents; Anticonvulsants; Chloride Channels; Humans; Hyperkalemia; Hyp | 2011 |
Acetazolamide-induced muscle weakness in hypokalemic periodic paralysis.
Topics: Acetazolamide; Acidosis, Renal Tubular; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Di | 2002 |